Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 3,000 shares, a decline of 55.9% from the December 31st total of 6,800 shares. Based on an average daily volume of 16,200 shares, the short-interest ratio is currently 0.2 days.
Adlai Nortye Stock Performance
ANL traded up $0.07 during trading on Friday, hitting $2.13. 1,603 shares of the company’s stock were exchanged, compared to its average volume of 11,598. The business’s 50 day moving average is $2.18 and its two-hundred day moving average is $2.47. Adlai Nortye has a fifty-two week low of $1.85 and a fifty-two week high of $17.48.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Adlai Nortye in a research report on Monday, November 11th.
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Further Reading
- Five stocks we like better than Adlai Nortye
- Where to Find Earnings Call Transcripts
- The Best Way to Invest in Gold Is…
- When to Sell a Stock for Profit or Loss
- Why Nike Stock Could Be 2025’s Top Comeback Play
- 3 Tickers Leading a Meme Stock Revival
- Uber Stock Gaining Speed: Analysts See 30% Upside
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
